---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301136"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:16:14.233042+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO

## Summary
- CEO Mussallem (70) to retire at May 11, 2023 annual meeting; will become non-executive chairman.
- Bernard Zovighian named President effective Jan 1, 2023, then CEO on May 11, 2023.
- Larry Wood expands to corporate VP and group president for TAVR and Surgical Structural Heart.
- Daveen Chopra to succeed Zovighian as head of Transcatheter Mitral & Tricuspid Therapies (TMTT).
- Zovighian base salary increased to $800k, incentive target $800k; Wood to $750k each.

## SEC filing metadata
- accession: 0001193125-22-301136
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/d423822d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301136
- JSON: https://secwatch.observer/filing/0001193125-22-301136.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301136.txt

## Key facts
- Executive change
  Larry Wood was appointed as Corporate Vice President and Group President at Edwards Lifesciences Corp.
  - Action: appointed to expanded role
  - Role: Corporate Vice President and Group President
  source text: the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm
- Executive change
  Bernard J. Zovighian was appointed as Chief Executive Officer at Edwards Lifesciences Corp.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm
- Executive change
  Bernard J. Zovighian was appointed as President at Edwards Lifesciences Corp.
  - Action: appointed
  - Role: President
  source text: On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm
- Executive change
  Michael A. Mussallem retired as Non-executive Chairman at Edwards Lifesciences Corp.
  - Action: retired
  - Role: Non-executive Chairman
  source text: On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.